Teva Pharmaceutical Industries company profile
Company profile
Teva Pharmaceutical Industries has 31,173 employees and is headquartered in Tel Aviv-Yafo, Israel.
Operating from Tel Aviv-Yafo, Israel, since its founding in 1901, the group works in generic medicines and biopharmaceutical products sold across the United States, Europe, Israel and other international markets. Its range covers tablets, capsules, injectables, inhalants, transdermal patches and creams, as well as sterile products, hormones and high-potency drugs. Among its brands are COPAXONE for multiple sclerosis, AUSTEDO for tardive dyskinesia, UZEDY for schizophrenia, AJOVY for migraine prevention, QVAR RediHaler for asthma and the over-the-counter SUDOCREM. Beyond finished medicines, it supplies active pharmaceutical ingredients, offers contract manufacturing and licenses products to other pharmaceutical companies.
In the fiscal year ended December 2025, revenue reached USD 17.3 billion, up 4.3% from the previous year, and net income was USD 1.4 billion. The United States accounted for 53.2% of revenue and Europe for 29.2%. The company had 31,173 employees.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Headquarters
- 124 Dvora HaNevi’a St., 6944020, Tel Aviv-Yafo
- Employees
- 31,173
- Chief executive
- Richard Francis
- Founded
- 1901
- Fiscal year
- January - December
- Listing
- TEVA · NYSE
- Currency
- USD
- ISIN
- IL0006290147
- Website
- tevapharm.com
Teva Pharmaceutical Industries and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Teva Pharmaceutical IndustriesTEVA | United States | $49.67B | 31,173 | 19.8% | 99.0 |
| ZoetisZTS | United States | $33.92B | 14,500 | 37.9% | 14.1 |
| United TherapeuticsUTHR | United States | $25.04B | 1,400 | 39.4% | 22.2 |
| ViatrisVTRS | United States | $23.58B | 30,000 | — | — |
| Neurocrine BiosciencesNBIX | United States | $16.73B | 2,500 | 26.6% | 24.5 |
| Hims & Hers HealthHIMS | United States | $4.13B | 2,442 | -6.4% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
